{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:14:02Z","timestamp":1788952442389,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00535-025-02313-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:34:52Z","timestamp":1762515292000},"page":"161-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9333-6729","authenticated-orcid":false,"given":"Atsushi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousaku","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Bamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Sagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Kanmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Asaeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Nagamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2313_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/bmj.285.6342.606","volume":"285","author":"DJ Davies","year":"1982","unstructured":"Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed). 1982;285:606. https:\/\/doi.org\/10.1136\/bmj.285.6342.606.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2313_CR2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/j.1572-0241.2006.00840.x","volume":"101","author":"GE Reese","year":"2006","unstructured":"Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410\u201322. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00840.x.","journal-title":"Am J Gastroenterol"},{"key":"2313_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12016-012-8349-4","volume":"45","author":"MT Arias-Loste","year":"2013","unstructured":"Arias-Loste MT, Bonilla G, Moraleja I, et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol. 2013;45:109\u201316. https:\/\/doi.org\/10.1007\/s12016-012-8349-4.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2313_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208974","volume":"13","author":"MP Horn","year":"2018","unstructured":"Horn MP, Peter AM, Righini Grunder F, et al. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn\u2019s disease. PLoS ONE. 2018;13:e0208974. https:\/\/doi.org\/10.1371\/journal.pone.0208974.","journal-title":"PLoS ONE"},{"key":"2313_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ibd.20054","volume":"13","author":"M Ferrante","year":"2007","unstructured":"Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123\u20138. https:\/\/doi.org\/10.1002\/ibd.20054.","journal-title":"Inflamm Bowel Dis"},{"key":"2313_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14423\/smj.0000000000000253","volume":"108","author":"DL Nguyen","year":"2015","unstructured":"Nguyen DL, Nguyen ET, Bechtold ML. pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD. South Med J. 2015;108:139\u201343. https:\/\/doi.org\/10.14423\/smj.0000000000000253.","journal-title":"South Med J"},{"key":"2313_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.14423\/smj.0000000000000252","volume":"108","author":"E Leung","year":"2015","unstructured":"Leung E. Commentary on \u201cpANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD.\u201d South Med J. 2015;108:144. https:\/\/doi.org\/10.14423\/smj.0000000000000252.","journal-title":"South Med J"},{"key":"2313_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cgh.2014.07.055","volume":"13","author":"MT Arias","year":"2015","unstructured":"Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.055.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2313_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/ajg.2010.95","volume":"105","author":"M J\u00fcrgens","year":"2010","unstructured":"J\u00fcrgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811\u20139. https:\/\/doi.org\/10.1038\/ajg.2010.95.","journal-title":"Am J Gastroenterol"},{"key":"2313_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jgh.12661","volume":"30","author":"D Kevans","year":"2015","unstructured":"Kevans D, Waterman M, Milgrom R, et al. Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis. J Gastroenterol Hepatol. 2015;30:64\u201370. https:\/\/doi.org\/10.1111\/jgh.12661.","journal-title":"J Gastroenterol Hepatol"},{"key":"2313_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152452","volume":"66","author":"S Mumtaz","year":"2024","unstructured":"Mumtaz S, Valecha J, Hochwald A, et al. Investigating the concomitance of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides and inflammatory bowel disease (IBD). Semin Arthritis Rheum. 2024;66:152452. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152452.","journal-title":"Semin Arthritis Rheum"},{"key":"2313_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5009\/gnl210211","volume":"16","author":"S Imakiire","year":"2022","unstructured":"Imakiire S, Takedatsu H, Mitsuyama K, et al. Role of serum proteinase 3 antineutrophil cytoplasmic antibodies in the diagnosis, evaluation of disease severity, and clinical course of ulcerative colitis. Gut Liver. 2022;16:92\u2013100. https:\/\/doi.org\/10.5009\/gnl210211.","journal-title":"Gut Liver"},{"key":"2313_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12876-021-01903-5","volume":"21","author":"Y Aoyama","year":"2021","unstructured":"Aoyama Y, Inaba T, Takahashi S, et al. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol. 2021;21:325. https:\/\/doi.org\/10.1186\/s12876-021-01903-5.","journal-title":"BMC Gastroenterol"},{"key":"2313_CR14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i21.3406","author":"JK Yamamoto-Furusho","year":"2006","unstructured":"Yamamoto-Furusho JK, Takahashi-Monroy T, Vergara-Fernandez O, et al. Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. World J Gastroenterol. 2006. https:\/\/doi.org\/10.3748\/wjg.v12.i21.3406.","journal-title":"World J Gastroenterol"},{"key":"2313_CR15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1572-0241.1999.01081.x","volume":"94","author":"K Sugi","year":"1999","unstructured":"Sugi K, Saitoh O, Matsuse R, et al. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol. 1999;94:1304\u201312. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01081.x.","journal-title":"Am J Gastroenterol"},{"key":"2313_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/196012","volume":"2013","author":"OI Saadah","year":"2013","unstructured":"Saadah OI, Al-Mughales JA. Pediatric inflammatory bowel disease with cytoplasmic staining of antineutrophil cytoplasmic antibodies. Clin Dev Immunol. 2013;2013:196012. https:\/\/doi.org\/10.1155\/2013\/196012.","journal-title":"Clin Dev Immunol"},{"key":"2313_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14140","author":"H Takedatsu","year":"2018","unstructured":"Takedatsu H, Mitsuyama K, Fukunaga S, et al. Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018. https:\/\/doi.org\/10.1111\/jgh.14140.","journal-title":"J Gastroenterol Hepatol"},{"key":"2313_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00054725-199911000-00002","volume":"5","author":"AN Elzouki","year":"1999","unstructured":"Elzouki AN, Eriksson S, L\u00f6fberg R, et al. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis. 1999;5:246\u201352. https:\/\/doi.org\/10.1097\/00054725-199911000-00002.","journal-title":"Inflamm Bowel Dis"},{"key":"2313_CR19","first-page":"169","volume":"21","author":"A Garc\u00eda-Herola","year":"1998","unstructured":"Garc\u00eda-Herola A, Nos P, Hoyos M, et al. Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn\u2019s disease. Gastroenterol Hepatol. 1998;21:169\u201373.","journal-title":"Gastroenterol Hepatol"},{"key":"2313_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13243682","author":"C Andaluc\u00eda","year":"2023","unstructured":"Andaluc\u00eda C, Mart\u00ednez-Prat L, Bentow C, et al. Clinical validity of anti-proteinase 3 antibodies in patients with inflammatory bowel disease: a short meta-analysis. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics13243682.","journal-title":"Diagnostics (Basel)"},{"key":"2313_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000515361","volume":"6","author":"A Yoshida","year":"2021","unstructured":"Yoshida A, Matsuoka K, Ueno F, et al. Serum PR3-ANCA is a predictor of primary nonresponse to anti-TNF-\u03b1 agents in patients with ulcerative colitis. Inflamm Intest Dis. 2021;6:117\u201322. https:\/\/doi.org\/10.1159\/000515361.","journal-title":"Inflamm Intest Dis"},{"key":"2313_CR22","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1038\/ajg.2010.345","volume":"105","author":"A Oussalah","year":"2010","unstructured":"Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617\u201325. https:\/\/doi.org\/10.1038\/ajg.2010.345.","journal-title":"Am J Gastroenterol"},{"key":"2313_CR23","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjv156","volume":"9","author":"T Billiet","year":"2015","unstructured":"Billiet T, Papamichael K, de Bruyn M, et al. A matrix-based model predicts primary response to Infliximab in Crohn\u2019s disease. J Crohns Colitis. 2015;9:1120\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv156.","journal-title":"J Crohns Colitis"},{"key":"2313_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/ecco-jcc\/jjw067","volume":"10","author":"K Papamichael","year":"2016","unstructured":"Papamichael K, Rivals-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to Infliximab. J Crohns Colitis. 2016;10:1015\u201323. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw067.","journal-title":"J Crohns Colitis"},{"key":"2313_CR25","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/ard.2004.033191","volume":"64","author":"M Haubitz","year":"2005","unstructured":"Haubitz M, Woywodt A, de Groot K, et al. Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis. Ann Rheum Dis. 2005;64:1500\u20132. https:\/\/doi.org\/10.1136\/ard.2004.033191.","journal-title":"Ann Rheum Dis"},{"key":"2313_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","volume":"14","author":"JP Gisbert","year":"2020","unstructured":"Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14:694\u2013709. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz195.","journal-title":"J Crohns Colitis"},{"key":"2313_CR27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/ibd\/izaa062","volume":"26","author":"L Bertani","year":"2020","unstructured":"Bertani L, Rossari F, Barberio B, et al. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Inflamm Bowel Dis. 2020;26:1579\u201387. https:\/\/doi.org\/10.1093\/ibd\/izaa062.","journal-title":"Inflamm Bowel Dis"},{"key":"2313_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1524307","volume":"12","author":"J Yan","year":"2025","unstructured":"Yan J, Wu J, Wang R, et al. The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab. Front Med (Lausanne). 2025;12:1524307. https:\/\/doi.org\/10.3389\/fmed.2025.1524307.","journal-title":"Front Med (Lausanne)"},{"key":"2313_CR29","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.ccr-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6212\u201322. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0442.","journal-title":"Clin Cancer Res"},{"key":"2313_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20139. https:\/\/doi.org\/10.1056\/NEJM198712243172603.","journal-title":"N Engl J Med"},{"key":"2313_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100094","volume":"4","author":"D Tsukui","year":"2021","unstructured":"Tsukui D, Kimura Y, Kono H. Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis. J Transl Autoimmun. 2021;4:100094. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100094.","journal-title":"J Transl Autoimmun"},{"key":"2313_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.103072","volume":"299","author":"G Carla","year":"2023","unstructured":"Carla G, Seren S, Lemoine R, et al. Constitutive and induced forms of membrane-bound proteinase 3 interact with antineutrophil cytoplasmic antibodies and promote immune activation of neutrophils. J Biol Chem. 2023;299:103072. https:\/\/doi.org\/10.1016\/j.jbc.2023.103072.","journal-title":"J Biol Chem"},{"key":"2313_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1046\/j.1365-2249.2000.01410.x","volume":"122","author":"F Moosig","year":"2000","unstructured":"Moosig F, Csernok E, Kumanovics G, et al. Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-\u03b1). Clin Exp Immunol. 2000;122:499\u2013503. https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01410.x.","journal-title":"Clin Exp Immunol"},{"key":"2313_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1046\/j.1365-2249.2002.01877.x","volume":"128","author":"BA Yard","year":"2002","unstructured":"Yard BA, Wille AI, Haak M, et al. Human proteinase 3 can inhibits LPS-mediated TNF-alpha production through CD14 degradation: lack of influence of antineutrophil cytoplasmic antibodies. Clin Exp Immunol. 2002;128:444\u201352. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01877.x.","journal-title":"Clin Exp Immunol"},{"key":"2313_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888763","volume":"13","author":"M Robert","year":"2022","unstructured":"Robert M, Miossec P, Hot A. The Th17 pathway in vascular inflammation: culprit or consort? Front Immunol. 2022;13:888763. https:\/\/doi.org\/10.3389\/fimmu.2022.888763.","journal-title":"Front Immunol"},{"key":"2313_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734.","journal-title":"N Engl J Med"},{"key":"2313_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","volume":"64","author":"T Wyant","year":"2015","unstructured":"Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64:77\u201383. https:\/\/doi.org\/10.1136\/gutjnl-2014-307127.","journal-title":"Gut"},{"issue":"Suppl 1","key":"2313_CR38","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1160\/ths10-11-0720","volume":"105","author":"AT Nurden","year":"2011","unstructured":"Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(Suppl 1):S13-33. https:\/\/doi.org\/10.1160\/ths10-11-0720.","journal-title":"Thromb Haemost"},{"key":"2313_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","volume":"81","author":"J Hanzel","year":"2021","unstructured":"Hanzel J, Ma C, Casteele NV, et al. Vedolizumab and extraintestinal manifestations in inflammatory bowel disease. Drugs. 2021;81:333\u201347. https:\/\/doi.org\/10.1007\/s40265-020-01460-3.","journal-title":"Drugs"},{"key":"2313_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, et al. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53:585\u201390. https:\/\/doi.org\/10.1007\/s00535-018-1449-z.","journal-title":"J Gastroenterol"},{"key":"2313_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00535-025-02216-0","volume":"60","author":"M Naganuma","year":"2025","unstructured":"Naganuma M, Shiga H, Shimoda M, et al. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study. J Gastroenterol. 2025;60:430\u201341. https:\/\/doi.org\/10.1007\/s00535-025-02216-0.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02313-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:41:32Z","timestamp":1771659692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02313-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2313"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02313-0","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Yoshida received personal fees from Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., EA Pharma Co., Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc, Mochida Pharmaceutical Co., Ltd. T. Takagi received research funding from Mitsubishi-Tanabe Pharma, and Pre. Media, Inc., and lecture fees from Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., EA Pharma Co., Ltd., Towa Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc, Mochida Pharmaceutical Co., Ltd.. S. Sagami received personal fees from Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., Takeda Pharmaceutical Co., Ltd. S. Ishihara received personal fees from Takeda Pharmaceutical Co. Ltd., Abbvie Inc.. K. Matsuoka has received personal fees from Mitsubishi-Tanabe Pharma, Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., AbbVie Inc., EA Pharma Co., Ltd, Pfizer Inc., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Gilead Sciences; research grants from Mitsubishi-Tanabe Pharma, AbbVie Inc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and has a leadership advisory role for EA Pharma Co., Ltd., Eli Lilly, Bristol-Myers Squibb, and Janssen Pharmaceutical K.K.. T. Hibi has received lecture fees from, Abbvie, EA Pharma, Janssen, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sandoz. Takeda Pharmaceutical, Zeria; advisory\/consultancy fees from Abbvie GK, Celltrion Healthcare Japan K.K., EA Pharma Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe Pharma, Nichi-Iko Pharmaceutical, Nippon Kayaku, Takeda, Zeria and research grants from Abbvie, Activaid, Alfresa Pharma Corporation, Bristol-Myers Squibb., Eli Lilly, Ferring, Gilead Sciences, JIMRO JMDC Inc., Janssen Pharmaceutical, Kyorin, Miyarisan., Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Zeria Pharmaceutical Co, Ltd.. Other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We conducted this study in compliance with the latest version (2013) of the Declaration of Helsinki. The study was approved by the ethics committee of Ofuna Chuo Hospital (No. 2020\u2013015, No. 2022-001, No. 2022-010). All enrolled patients provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}